Clinical Trial Activity In Emerging Markets Deemed Minor Against Global Backdrop - ACRO
This article was originally published in PharmAsia News
Executive Summary
The Association of Clinical Research Organizations is distancing itself from a notion that a "high degree" of clinical trial work is conducted in emerging markets
You may also be interested in...
Will Spiraling Costs Retard Growth Of Clinical Research In India? The Jury Is Out
MUMBAI - From being a preferred destination for conducting clinical research to facing competitive pressure from countries like Malaysia, the Indian clinical research industry may miss the opportunity of emerging as a global hub for multinational drug companies
Will Spiraling Costs Retard Growth Of Clinical Research In India? The Jury Is Out
MUMBAI - From being a preferred destination for conducting clinical research to facing competitive pressure from countries like Malaysia, the Indian clinical research industry may miss the opportunity of emerging as a global hub for multinational drug companies
Clinical Research Is Booming In India But Are There Enough IRBs?
MUMBAI - Over the past decade, India's clinical research industry has grown at a compound annual rate of 64 percent, zooming up from just $12 million in 2001 to an estimated billion-plus dollars by next year. But that meteoric rise may be putting pressure on Institutional Review Boards entrusted with approval of clinical trials and some industry experts are now asking for better controls over IRBs, or ethics review boards